Biotechnology venture capital funding continued a multi-year surge in the first half of 2026, as strong public market performance and a spike in dealmaking activity helped spur interest in privately held drug startups, BioPharma Dive data show.

Data compiled by BioPharma Dive indicate that at least 68 biotech companies banked more than $9.1 billion in venture capital funding between January and June. The total amount raised represents the highest first-half sum since the start of 2022, among companies backed by the 26 firms BioPharma Dive tracks. READ MORE